Heart drug digoxin fails to show promise for alcohol hepatitis in small trial
NCT ID NCT05014087
First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 22 times
Summary
This study tested whether digoxin, a heart medication, could reduce inflammation in people with severe alcohol-related hepatitis. 23 adults were randomly assigned to receive digoxin or no digoxin for up to 28 days. The trial was stopped early, and the main goal was to measure changes in inflammatory markers in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ALCOHOLIC HEPATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yale New Haven Hospital, Yale School of Medicine
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.